The pro- and anti-tumor role of ILC2s

被引：22

作者：

Trabanelli, Sara ^{[1
]}

Chevalier, Mathieu F. ^{[2
,3
,4
]}

Derre, Laurent ^{[2
]}

Jandus, Camilla ^{[1
]}

机构：

[1] Univ Lausanne, UNIL CHUV, Dept Oncol, CH-1066 Epalinges, Switzerland

[2] Univ Hosp Lausanne CHUV, Urol Res Unit, CH-1011 Lausanne, Switzerland

[3] Hop St Louis, Lab Human Immunol Pathophysiol & Immunotherapy, INSERM U976, Paris, France

[4] Univ Paris, Hop St Louis, Inst Rech St Louis, Paris, France

来源：

SEMINARS IN IMMUNOLOGY | 2019年 / 41卷

基金：

瑞士国家科学基金会;

关键词：

Group-2 innate lymphoid cells; ILC2; Cancer; Tumor immunoregulation; INNATE LYMPHOID-CELLS; TRANSCRIPTION FACTOR BCL11B; T-CELLS; TYPE-2; IMMUNITY; FACTOR GATA3; INFLAMMATION; EXPRESSION; GROWTH; IL-33; CARCINOGENESIS;

D O I：

10.1016/j.smim.2019.04.004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Group 2 innate lymphoid cells (ILC2s) are critical for the initiation of type 2 inflammatory diseases. However, ILC2s are also involved in the establishment of the immune microenvironment during tumor development, growth and metastasization. In this context, ILC2s have been shown to be either tumor-suppressive or tumor-promoting according to the tumor type, the cytokine secreted and the other immune cells that are, in turn, recruited and/or activated.

引用

页数：6

共 50 条

[1] GUT DYSBIOSIS SUPPRESSES ANTI-TUMOR ILC2S IN PANCREATIC CANCER
Zebboudj, Abderezak
Amisaki, Masataka
Guasp, Pablo
Rojas, Luis
Sethna, Zachari
Theresa, Waters
Chandra, Adrienne
Yu, Rebecca
Odgerel, Zagaa
Soares, Kevin
Balachandran, Vinod
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1363 - A1363
[2] ILC2s: New Actors in Tumor Immunity
Ercolano, Giuseppe
Falquet, Maryline
Vanoni, Giulia
Trabanelli, Sara
Jandus, Camilla
FRONTIERS IN IMMUNOLOGY, 2019, 10
[3] Therapeutic IL-33 enhances the antigen presentation function of ILC2s to exert anti-tumor immune activity
Liu, Jie
Feng, Zhenchu
Wei, Hongyan
Li, Chang
Li, Xiaoshi
Chen, Wenlong
Ke, Yixi
Wang, Minjun
Liu, Lantian
Zheng, Cunni
Liu, Quan
CANCER RESEARCH, 2024, 84 (06)
[4] CRACing the role of calcium signaling in ILC2s
Falduto, Guido H.
Schwartz, Daniella M.
CELL CALCIUM, 2024, 117
[5] Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance
Furumaya, Charita
Martinez-Sanz, Paula
Bouti, Panagiota
Kuijpers, Taco W.
Matlung, Hanke L.
FRONTIERS IN IMMUNOLOGY, 2020, 11
[6] Mathematical modeling and bifurcation analysis of pro- and anti-tumor macrophages
Shu, Yaqin
Huang, Jicai
Dong, Yueping
Takeuchi, Yasuhiro
APPLIED MATHEMATICAL MODELLING, 2020, 88 : 758 - 773
[7] Neuroregulation of ILC2s
Dempsey, Laurie A.
NATURE IMMUNOLOGY, 2018, 19 (04) : 316 - 316
[8] Neuroregulation of ILC2s
Laurie A. Dempsey
Nature Immunology, 2018, 19 : 316 - 316
[9] Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor
Narasimhan, Supraja
Zulick, Elizabeth Stanford
Novikov, Olga
Parks, Ashley J.
Schlezinger, Jennifer J.
Wang, Zhongyan
Laroche, Fabrice
Feng, Hui
Mulas, Francesca
Monti, Stefano
Sherr, David H.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (05)
[10] Role of ILC2s in Solid Tumors: Facilitate or Inhibit?
Wu, Lige
Zhao, Weiqing
Tang, Shuxian
Chen, Rui
Ji, Mei
Yang, Xin
FRONTIERS IN IMMUNOLOGY, 2022, 13

← 1 2 3 4 5 →